Nexalin Stock (NASDAQ:NXL)


RevenueOwnershipFinancialsChart

Previous Close

$0.63

52W Range

$0.25 - $4.05

50D Avg

$0.88

200D Avg

$0.94

Market Cap

$6.96M

Avg Vol (3M)

$231.87K

Beta

5.71

Div Yield

-

NXL Company Profile


Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Sep 16, 2022

Website

NXL Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
Other$1.37K$26.41K
Equipment$27.30K$26.78K
Licensing Fee$82.08K$79.19K
Device Sales-$1.16M

Fiscal year ends in Dec 23 | Currency in USD

NXL Financial Summary


Dec 23Dec 22Dec 21
Revenue$110.75K$1.32M$144.06K
Operating Income$-5.70M$-1.83M$-6.02M
Net Income$-4.65M$-1.93M$-6.16M
EBITDA$-5.70M$-1.66M$-6.02M
Basic EPS$-0.63$-0.35$-0.85
Diluted EPS$-0.63$-0.35$-0.85

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
AIMDAinos, Inc.
INVOINVO Bioscience, Inc.
LNSRLENSAR, Inc.
SSKNSTRATA Skin Sciences, Inc.
MODDModular Medical, Inc.
IRIXIRIDEX Corporation
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
LIVNLivaNova PLC
KIDSOrthoPediatrics Corp.
OSAProSomnus, Inc. Common Stock
AZYOElutia Inc.
BJDXBluejay Diagnostics, Inc.
MOTSMotus GI Holdings, Inc.